FluGen, a Madison company that specializes in technology to prevent and treat flu viruses, said Tuesday it has gained rights from the Wisconsin Alumni Research Foundation to a new class of antiviral drugs with a wider time window for therapeutic action. The technology was developed at UW-Madison and patented through WARF.
Office of Strategic Communication